Anthony R. French, M.D., Ph.D.

Profile picture
Division Chief, Rheumatology
Researcher, Pathobiology
Associate Professor of Pediatrics, Pathology & Immunology, and Biomedical Engineering, Washington University School of Medicine

phone: (314) 454-6124

Clinical Interests

Anthony R. French received his M.D. and Ph.D. degrees from the University of Illinois at Urbana-Champaign. His graduate work was with Dr. Douglas Lauffenburger studying receptor-mediated endocytosis and intracellular sorting. He completed his residency in Pediatrics at the Mayo Clinic in Rochester, MN and his fellowship in Pediatric Rheumatology at Washington University School of Medicine in St. Louis, MO. His clinical interests include juvenile rheumatoid arthritis, juvenile dermatomyositis, vasculitis, and pediatric SLE. His research is focused on the role of natural killer (NK) cells in the early innate immune response and is motivated by the hypothesis that a clearer understanding of in vivo NK cell responses and homeostasis may lead to novel therapeutic interventions in autoimmune diseases.


  • BS, University of Minnesota1989
  • MSc, University of Illinois1993
  • PhD, University of Illinois1995
  • MD, University of Illinois1997


  • Residency, Mayo Graduate School of Medicine1997 - 2000
  • Fellow, Pediatric Rheumatology, Washington University School of Medicine2000 - 2003

Licensure and Board Certification

  • American Board of Pediatrics 2000
  • MO, Physician and Surgeon 2003
  • Pediatric Rheumatology 2004


  • Procter and Gamble Fellowship1990 - 1991
  • Chevron Fellowship1991 - 1992
  • Alpha Omega Alpha1996
  • Lange Medical Pub. Award for Outstanding Performance in Medical School1997
  • Ross Award for Excellence in Pediatrics1997
  • Yardy Award for Excellence in Family Medicine1997
  • Howard Hughes Medical Institute (HHMI) Faculty Development Award2002 - 2005
  • Scholar, Child Health Research Center of Excellence, Washington Univ2006 - 2008
  • Basil O'Connor Scholar Award, March of Dimes2007 - 2009
  • Elected to Society of Pediatric Research2010
  • Elected to American Society for Clinical Investigation2014

Recent Publications view all (53)

Publication Co-Authors

  1. Epidemiology and Outcomes of Granulomatosis with Polyangiitis (GPA) in Pediatric and Working-age Adult Populations in the United States: Analysis of a Large National Claims Database 2018. PMID:29806148 
  2. Identification of Enhanced Interferon-Gamma Signaling in Polyarticular Juvenile Idiopathic Arthritis with Mass Cytometry in press. 2018. 
  3. Comment on: Evidence of innate lymphoid cell redundancy in humans. Nat Imm, in press. 2018;19(8):788-789. PMID:30026477 
  4. Proteomic and phylogenetic coevolution analyses of pM79 and pM92 identify interactions with RNA polymerase II and delineate the murine cytomegalovirus late transcription complex. J Gen Virol. 2017;98(2):242-250. PMID:27926822 
  5. Deficiency of the adaptor protein SLy1 results in a natural killer cell ribosomopathy affecting tumor clearance. Oncoimmunology. 2016;5(12):e1238543. PMCID:PMC5215235  PMID:28123874 
  6. Four cases of anti-PM/Scl antibody positive juvenile overlap syndrome with features of myositis and systemic sclerosis. J Rheum. 2016. PMID:27587018 
  7. Mesenteric vasculitis in children with systemic lupus erythematosus. Clin Rheumatol. 2016;35(3):785-93. PMID:25687984 
  8. Type I interferons link viral infection to enhanced epithelial turnover and repair. Cell Host Microbe. 2015;17(1):85-97. doi:10.1016/j.chom.2014.11.004  PMCID:PMC4297260  PMID:25482432 
  9. Elevated double negative T cells in pediatric autoimmunity. J Clin Immunol. 2014;34(5):594-9. doi:10.1007/s10875-014-0038-z  PMCID:PMC4047151  PMID:24760111 
  10. Murine cytomegalovirus protein pM92 is a conserved regulator of viral late gene expression. J Virol. 2014;88(1):131-42. doi:10.1128/JVI.02684-13  PMCID:PMC3911726  PMID:24131717 
  11. MicroRNA-155 tunes both the threshold and extent of NK cell activation via targeting of multiple signaling pathways. J Immunol. 2013;191(12):5904-13. doi:10.4049/jimmunol.1301950  PMCID:PMC3863634  PMID:24227772 
  12. Hypogammaglobulinemia in pediatric systemic lupus erythematosus. Lupus. 2013;22(13):1382-7. doi:10.1177/0961203313507990  PMCID:PMC3840537  PMID:24106215 
  13. Markers of nonselective and specific NK cell activation. J Immunol. 2013;190(12):6269-76. doi:10.4049/jimmunol.1202533  PMCID:PMC3679313  PMID:23656738 
  14. Natural killer cell functional defects in pediatric patients with severe and recurrent herpesvirus infections. J Infect Dis. 2013;207(3):458-68. doi:10.1093/infdis/jis701  PMCID:PMC3693586  PMID:23175766 
  15. Inositol tetrakisphosphate limits NK cell effector functions by controlling PI3K signaling. Blood. 2013;121(2):286-97. doi:10.1182/blood-2012-05-429241  PMCID:PMC3544114  PMID:23175687 
  16. Mechanistic model of natural killer cell proliferative response to IL-15 receptor stimulation. PLoS Comput Biol. 2013;9(9):e1003222. doi:10.1371/journal.pcbi.1003222  PMCID:PMC3772054  PMID:24068905 
  17. The use of electroconvulsive therapy in a patient with juvenile systemic lupus erythematosus and catatonia. Lupus. 2012;21(14):1575-81. doi:10.1177/0961203312464803  PMID:23161578 
  18. Sex differences in murine susceptibility to systemic viral infections. J Autoimmun. 2012;38(2-3):J245-53. doi:10.1016/j.jaut.2011.12.003  PMCID:PMC3313007  PMID:22209097 
  19. Two-compartment model of NK cell proliferation: insights from population response to IL-15 stimulation. J Immunol. 2012;188(7):2981-90. doi:10.4049/jimmunol.1102989  PMCID:PMC3311749  PMID:22379026 
  20. MicroRNA-deficient NK cells exhibit decreased survival but enhanced function. J Immunol. 2012;188(7):3019-30. doi:10.4049/jimmunol.1102294  PMCID:PMC3311726  PMID:22379033 
  21. Activation mechanisms of natural killer cells during influenza virus infection. PLoS One. 2012;7(12):e51858. doi:10.1371/journal.pone.0051858  PMCID:PMC3534084  PMID:23300570 
  22. Recurrent parotitis as a presentation of primary pediatric Sjögren syndrome. Pediatrics. 2012;129(1):e179-82. doi:10.1542/peds.2011-0716  PMID:22184654 
  23. Clinical outcomes after withdrawal of anti-tumor necrosis factor α therapy in patients with juvenile idiopathic arthritis: a twelve-year experience. Arthritis Rheum. 2011;63(10):3163-8. doi:10.1002/art.30502  PMID:21702011 
  24. Cutting edge: FcR-like 5 on innate B cells is targeted by a poxvirus MHC class I-like immunoevasin. J Immunol. 2010;185(1):28-32. doi:10.4049/jimmunol.1000240  PMCID:PMC3321838  PMID:20519648 
  25. Ly49H engagement compensates for the absence of type I interferon signaling in stimulating NK cell proliferation during murine cytomegalovirus infection. J Immunol. 2009;183(9):5830-6. doi:10.4049/jimmunol.0901520  PMCID:PMC2765556  PMID:19828630 
  26. Differential expression of granzyme B and C in murine cytotoxic lymphocytes. J Immunol. 2009;182(10):6287-97. doi:10.4049/jimmunol.0804333  PMCID:PMC2714542  PMID:19414782 
  27. Ly49h is necessary for genetic resistance to murine cytomegalovirus. Immunogenetics. 2008;60(10):565-73. doi:10.1007/s00251-008-0313-3  PMCID:PMC2730736  PMID:18668236 
  28. HLA alleles determine differences in human natural killer cell responsiveness and potency. Proc Natl Acad Sci U S A. 2008;105(8):3053-8. doi:10.1073/pnas.0712229105  PMCID:PMC2268583  PMID:18287063 
  29. Chronic lymphocytosis of functionally immature natural killer cells. J Allergy Clin Immunol. 2007;120(4):924-31. doi:10.1016/j.jaci.2007.05.022  PMID:17604094 
  30. Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients. Arthritis Rheum. 2007;56(9):3107-11. doi:10.1002/art.22856  PMID:17763414 
  31. Acquisition of murine NK cell cytotoxicity requires the translation of a pre-existing pool of granzyme B and perforin mRNAs. Immunity. 2007;26(6):798-811. doi:10.1016/j.immuni.2007.04.010  PMID:17540585 
  32. Histoplasmosis in a child with JRA on low-dose methotrexate. Rheumatology (Oxford). 2007;46(1):177-8. doi:10.1093/rheumatology/kel375  PMID:17114804 
  33. DAP12 signaling directly augments proproliferative cytokine stimulation of NK cells during viral infections. J Immunol. 2006;177(8):4981-90. PMID:17015680 
  34. IL-18 acts synergistically with IL-15 in stimulating natural killer cell proliferation. Cytokine. 2006;35(5-6):229-34. doi:10.1016/j.cyto.2006.08.006  PMID:17052916 
  35. Arrested natural killer cell development associated with transgene insertion into the Atf2 locus. Blood. 2006;107(3):1024-30. doi:10.1182/blood-2005-04-1493  PMCID:PMC1458371  PMID:16223777 
  36. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature. 2005;436(7051):709-13. doi:10.1038/nature03847  PMID:16079848 
  37. A lymphotoxin-IFN-beta axis essential for lymphocyte survival revealed during cytomegalovirus infection. J Immunol. 2005;174(11):7217-25. PMID:15905567 
  38. Rapid emergence of escape mutants following infection with murine cytomegalovirus in immunodeficient mice. Clin Immunol. 2005;115(1):61-9. doi:10.1016/j.clim.2005.02.008  PMID:15870022 
  39. TLR9-dependent recognition of MCMV by IPC and DC generates coordinated cytokine responses that activate antiviral NK cell function. Immunity. 2004;21(1):107-19. doi:10.1016/j.immuni.2004.06.007  PMID:15345224 
  40. Escape of mutant double-stranded DNA virus from innate immune control. Immunity. 2004;20(6):747-56. doi:10.1016/j.immuni.2004.05.006  PMID:15189739 
  41. Coordinate expression of cytokines and chemokines by NK cells during murine cytomegalovirus infection. J Immunol. 2004;172(5):3119-31. PMID:14978118 
  42. In vivo developmental stages in murine natural killer cell maturation. Nat Immunol. 2002;3(6):523-8. doi:10.1038/ni796  PMID:12006976 
  43. Osteopenia in adults with a history of juvenile rheumatoid arthritis. A population based study. J Rheumatol. 2002;29(5):1065-70. PMID:12022324 
  44. Increased mortality in adults with a history of juvenile rheumatoid arthritis: a population-based study. Arthritis Rheum. 2001;44(3):523-7. doi:10.1002/1529-0131(200103)44:3<523::AID-ANR99>3.0.CO;2-1  PMID:11263765 
  45. Controlling receptor/ligand trafficking: effects of cellular and molecular properties on endosomal sorting. Ann Biomed Eng. 1997;25(4):690-707. PMID:9236981 
  46. Engineering dynamics of growth factors and other therapeutic ligands. Biotechnol Bioeng. 1996;52(1):61-80. doi:10.1002/(SICI)1097-0290(19961005)52:1<61::AID-BIT6>3.0.CO;2-X  PMID:18629852 
  47. Intracellular receptor/ligand sorting based on endosomal retention components. Biotechnol Bioeng. 1996;51(3):281-97. doi:10.1002/(SICI)1097-0290(19960805)51:3<281::AID-BIT4>3.0.CO;2-9  PMID:18624361 
  48. Intracellular trafficking of epidermal growth factor family ligands is directly influenced by the pH sensitivity of the receptor/ligand interaction. J Biol Chem. 1995;270(9):4334-40. PMID:7876195 
  49. Postendocytic trafficking of epidermal growth factor-receptor complexes is mediated through saturable and specific endosomal interactions. J Biol Chem. 1994;269(22):15749-55. PMID:8195228 
  50. Myosin cross-bridge orientation in rigor and in the presence of nucleotide studied by electron spin resonance. Biophys J. 1989;56(3):535-41. doi:10.1016/S0006-3495(89)82700-6  PMCID:PMC1280506  PMID:2551407 
  51. Reconstruction of the probe angular distribution from a series of electron spin resonance spectra of tilted oriented samples. Biophys J. 1989;56(3):525-34. doi:10.1016/S0006-3495(89)82699-2  PMCID:PMC1280505  PMID:2551406 
  52. Serologic Evidence of Gut-driven Systemic Inflammation in Juvenile Idiopathic Arthritis J Rheum 2017. 44(11):1624-31. PMID:28916545 
  53. Glycolytic requirement for NK cell cytotoxicity and cytomegalovirus control. JCI Insight 2017. PMID:29212951 
Last updated: 08/03/2018
© 2018 by Washington University in St. Louis
One Brookings Drive, St. Louis, MO 63130